drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00342 | DB08864 | 1,181 | 786 | [
"DDInter1770",
"DDInter1595"
] | Terfenadine | Rilpivirine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
1181,
24,
786
]
],
[
[
1181,
24,
655
],
[
655,
1,
786
]
],
[
[
1181,
23,
112
],
[
112,
23,
786
]
],
[
[
1181,
24,
1017
],
[
1017,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that c... |
DB06636 | DB14568 | 1,623 | 982 | [
"DDInter980",
"DDInter1000"
] | Isavuconazonium | Ivosidenib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1623,
25,
982
]
],
[
[
1623,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1623,
24,
976
],
[
976,
24,
982
]
],
[
[
1623,
63,
543
],
[
543,
... | [
[
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib a... |
DB00060 | DB00851 | 912 | 611 | [
"DDInter947",
"DDInter463"
] | Interferon beta-1a | Dacarbazine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
912,
24,
611
]
],
[
[
912,
24,
1176
],
[
1176,
23,
611
]
],
[
[
912,
24,
850
],
[
850,
63,
611
]
],
[
[
912,
63,
305
],
[
305,
2... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxac... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Dacarbazine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Br... |
DB05773 | DB08889 | 1,047 | 350 | [
"DDInter1848",
"DDInter299"
] | Trastuzumab emtansine | Carfilzomib | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
1047,
24,
350
]
],
[
[
1047,
24,
1060
],
[
1060,
63,
350
]
],
[
[
1047,
63,
482
],
[
482,
24,
350
]
],
[
[
1047,
24,
310
],
[
310,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfo... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate disease... |
DB01069 | DB12161 | 401 | 730 | [
"DDInter1533",
"DDInter512"
] | Promethazine | Deutetrabenazine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Major | 2 | [
[
[
401,
25,
730
]
],
[
[
401,
62,
112
],
[
112,
23,
730
]
],
[
[
401,
63,
322
],
[
322,
24,
730
]
],
[
[
401,
24,
971
],
[
971,
24,... | [
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubici... |
DB00852 | DB08918 | 1,445 | 41 | [
"DDInter1545",
"DDInter1059"
] | Pseudoephedrine | Levomilnacipran | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
1445,
24,
41
]
],
[
[
1445,
24,
901
],
[
901,
40,
41
]
],
[
[
1445,
6,
6112
],
[
6112,
45,
41
]
],
[
[
1445,
21,
28975
],
[
28975,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Pseudoephedrine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Levomilnacipran (Compound)
Pseudoephedrine (Compound) causes Tension (S... |
DB00031 | DB00790 | 20 | 664 | [
"DDInter1764",
"DDInter1431"
] | Tenecteplase | Perindopril | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Moderate | 1 | [
[
[
20,
24,
664
]
],
[
[
20,
24,
1638
],
[
1638,
1,
664
]
],
[
[
20,
24,
954
],
[
954,
40,
664
]
],
[
[
20,
24,
885
],
[
885,
63,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (Co... |
DB00227 | DB06186 | 1,463 | 1,439 | [
"DDInter1098",
"DDInter969"
] | Lovastatin | Ipilimumab | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
1463,
24,
1439
]
],
[
[
1463,
63,
912
],
[
912,
24,
1439
]
],
[
[
1463,
24,
482
],
[
482,
24,
1439
]
],
[
[
1463,
24,
310
],
[
310,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Tiogu... |
DB00491 | DB00701 | 127 | 1,091 | [
"DDInter1217",
"DDInter90"
] | Miglitol | Amprenavir | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Amprenavir is a protease inhibitor used to treat HIV infection. | Moderate | 1 | [
[
[
127,
24,
1091
]
],
[
[
127,
24,
34
],
[
34,
1,
1091
]
],
[
[
127,
21,
28810
],
[
28810,
60,
1091
]
],
[
[
127,
24,
222
],
[
222,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Miglitol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Amprenavir (Compound)
Miglitol may cause... |
DB09115 | DB09570 | 505 | 1,480 | [
"DDInter559",
"DDInter1002"
] | Diiodohydroxyquinoline | Ixazomib | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
505,
24,
1480
]
],
[
[
505,
63,
268
],
[
268,
24,
1480
]
],
[
[
505,
24,
148
],
[
148,
63,
1480
]
],
[
[
505,
63,
375
],
[
375,
... | [
[
[
"Diiodohydroxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Diiodohydroxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegin... | Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate di... |
DB00035 | DB00477 | 1,314 | 216 | [
"DDInter507",
"DDInter363"
] | Desmopressin | Chlorpromazine | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
1314,
24,
216
]
],
[
[
1314,
24,
1237
],
[
1237,
40,
216
]
],
[
[
1314,
24,
1164
],
[
1164,
1,
216
]
],
[
[
1314,
21,
28751
],
[
28751... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Chlorpromazine (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Chlorp... |
DB01226 | DB01233 | 1,319 | 1,311 | [
"DDInter1235",
"DDInter1197"
] | Mivacurium | Metoclopramide | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1319,
24,
1311
]
],
[
[
1319,
21,
28680
],
[
28680,
60,
1311
]
],
[
[
1319,
63,
1620
],
[
1620,
23,
1311
]
],
[
[
1319,
21,
28680
],
[
... | [
[
[
"Mivacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Mivacurium",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by ... | Mivacurium (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Metoclopramide (Compound)
Mivacurium may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Metoclopram... |
DB00163 | DB08871 | 1,461 | 36 | [
"DDInter1943",
"DDInter666"
] | Vitamin E | Eribulin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1461,
24,
36
]
],
[
[
1461,
24,
1488
],
[
1488,
24,
36
]
],
[
[
1461,
23,
1683
],
[
1683,
24,
36
]
],
[
[
1461,
24,
1480
],
[
1480,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab and Ustekinum... |
DB05294 | DB06603 | 1,069 | 39 | [
"DDInter1917",
"DDInter1387"
] | Vandetanib | Panobinostat | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1069,
25,
39
]
],
[
[
1069,
62,
1247
],
[
1247,
23,
39
]
],
[
[
1069,
63,
479
],
[
479,
23,
39
]
],
[
[
1069,
63,
867
],
[
867,
... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulf... | Vandetanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil a... |
DB08901 | DB09118 | 1,468 | 1,580 | [
"DDInter1492",
"DDInter1711"
] | Ponatinib | Stiripentol | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1468,
24,
1580
]
],
[
[
1468,
64,
1409
],
[
1409,
24,
1580
]
],
[
[
1468,
25,
283
],
[
283,
63,
1580
]
],
[
[
1468,
63,
168
],
[
168,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Ponatinib may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ponatinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interacti... |
DB00734 | DB14723 | 1,664 | 159 | [
"DDInter1605",
"DDInter1026"
] | Risperidone | Larotrectinib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1664,
24,
159
]
],
[
[
1664,
24,
222
],
[
222,
23,
159
]
],
[
[
1664,
24,
741
],
[
741,
24,
159
]
],
[
[
1664,
63,
1181
],
[
1181,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and R... |
DB00372 | DB00477 | 999 | 216 | [
"DDInter1793",
"DDInter363"
] | Thiethylperazine | Chlorpromazine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
999,
24,
216
]
],
[
[
999,
24,
1178
],
[
1178,
1,
216
]
],
[
[
999,
63,
902
],
[
902,
40,
216
]
],
[
[
999,
24,
1216
],
[
1216,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluopera... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles ... |
DB00910 | DB06448 | 1,041 | 171 | [
"DDInter1394",
"DDInter1087"
] | Paricalcitol | Lonafarnib | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
1041,
24,
171
]
],
[
[
1041,
24,
98
],
[
98,
63,
171
]
],
[
[
1041,
24,
86
],
[
86,
24,
171
]
],
[
[
1041,
24,
129
],
[
129,
64,... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Micona... |
DB01159 | DB04868 | 419 | 478 | [
"DDInter854",
"DDInter1293"
] | Halothane | Nilotinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
419,
25,
478
]
],
[
[
419,
6,
6017
],
[
6017,
45,
478
]
],
[
[
419,
62,
112
],
[
112,
23,
478
]
],
[
[
419,
24,
1040
],
[
1040,
... | [
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"... | Halothane (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Halothane may cause ... |
DB01144 | DB08907 | 1,326 | 1,344 | [
"DDInter540",
"DDInter280"
] | Diclofenamide | Canagliflozin | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1326,
24,
1344
]
],
[
[
1326,
24,
549
],
[
549,
1,
1344
]
],
[
[
1326,
21,
28680
],
[
28680,
60,
1344
]
],
[
[
1326,
63,
1486
],
[
148... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Diclofenamide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)
Diclofenamide may cause a moderate i... |
DB01114 | DB14881 | 272 | 180 | [
"DDInter362",
"DDInter1329"
] | Chlorpheniramine | Oliceridine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
272,
24,
180
]
],
[
[
272,
63,
401
],
[
401,
24,
180
]
],
[
[
272,
24,
649
],
[
649,
24,
180
]
],
[
[
272,
74,
100
],
[
100,
24,... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clof... |
DB00848 | DB15091 | 281 | 676 | [
"DDInter1044",
"DDInter1901"
] | Levamisole | Upadacitinib | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
281,
25,
676
]
],
[
[
281,
24,
1430
],
[
1430,
24,
676
]
],
[
[
281,
63,
597
],
[
597,
24,
676
]
],
[
[
281,
63,
1184
],
[
1184,
... | [
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipule... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol... |
DB00861 | DB01240 | 914 | 885 | [
"DDInter551",
"DDInter657"
] | Diflunisal | Epoprostenol | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
914,
24,
885
]
],
[
[
914,
63,
1061
],
[
1061,
1,
885
]
],
[
[
914,
21,
28936
],
[
28936,
60,
885
]
],
[
[
914,
63,
1512
],
[
1512,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Diflunisal (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Diflunisal may cause a moder... |
DB01082 | DB14115 | 1,448 | 1,312 | [
"DDInter1713",
"DDInter868"
] | Streptomycin | Human botulinum neurotoxin A/B immune globulin | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle t... | Major | 2 | [
[
[
1448,
25,
1312
]
],
[
[
1448,
24,
123
],
[
123,
24,
1312
]
],
[
[
1448,
63,
1132
],
[
1132,
25,
1312
]
],
[
[
1448,
35,
416
],
[
416,
... | [
[
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human botulinum neurotoxin A/B immune globulin"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ex... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Streptomycin may cause a moderate interaction that could exacerbate diseases... |
DB00787 | DB09134 | 387 | 1,552 | [
"DDInter25",
"DDInter966"
] | Acyclovir | Ioversol | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
387,
25,
1552
]
],
[
[
387,
24,
242
],
[
242,
63,
1552
]
],
[
[
387,
40,
1295
],
[
1295,
25,
1552
]
],
[
[
387,
24,
1381
],
[
1381,
... | [
[
[
"Acyclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
... | Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Acyclovir (Compound) resembles Valaciclovir (Compound) and Valaciclovir may lead to a major life threatening intera... |
DB00678 | DB01075 | 240 | 1,376 | [
"DDInter1095",
"DDInter569"
] | Losartan | Diphenhydramine | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
240,
24,
1376
]
],
[
[
240,
24,
401
],
[
401,
24,
1376
]
],
[
[
240,
6,
10215
],
[
10215,
45,
1376
]
],
[
[
240,
21,
28921
],
[
28921,... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Losartan (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Diphenhydramine (Compound)
Losart... |
DB00731 | DB00741 | 1,144 | 167 | [
"DDInter1269",
"DDInter885"
] | Nateglinide | Hydrocortisone | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1144,
24,
167
]
],
[
[
1144,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1144,
63,
303
],
[
303,
40,
167
]
],
[
[
1144,
63,
870
],
[
870,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone aceta... |
DB09074 | DB09098 | 1,362 | 98 | [
"DDInter1327",
"DDInter1700"
] | Olaparib | Somatrem | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1362,
24,
98
]
],
[
[
1362,
63,
608
],
[
608,
23,
98
]
],
[
[
1362,
63,
336
],
[
336,
24,
98
]
],
[
[
1362,
24,
159
],
[
159,
63... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Li... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may c... |
DB00619 | DB09143 | 1,419 | 313 | [
"DDInter909",
"DDInter1701"
] | Imatinib | Sonidegib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
1419,
25,
313
]
],
[
[
1419,
24,
101
],
[
101,
23,
313
]
],
[
[
1419,
63,
1215
],
[
1215,
23,
313
]
],
[
[
1419,
35,
478
],
[
478,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansopr... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and L... |
DB00402 | DB01081 | 1,407 | 1,688 | [
"DDInter685",
"DDInter571"
] | Eszopiclone | Diphenoxylate | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | Moderate | 1 | [
[
[
1407,
24,
1688
]
],
[
[
1407,
24,
1118
],
[
1118,
1,
1688
]
],
[
[
1407,
24,
128
],
[
128,
24,
1688
]
],
[
[
1407,
63,
1594
],
[
1594,... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin and Difenoxin (Compound) resembles Diphenoxylate (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate int... |
DB00209 | DB01324 | 352 | 178 | [
"DDInter1886",
"DDInter1490"
] | Trospium | Polythiazide | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Minor | 0 | [
[
[
352,
23,
178
]
],
[
[
352,
23,
674
],
[
674,
40,
178
]
],
[
[
352,
21,
28714
],
[
28714,
60,
178
]
],
[
[
352,
24,
85
],
[
85,
2... | [
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
]
],
[
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
],
[
... | Trospium may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Trospium (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Polythiazide (Compound)
Trospium may cause a moderate in... |
DB00039 | DB00112 | 1,253 | 374 | [
"DDInter1380",
"DDInter201"
] | Palifermin | Bevacizumab | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its at... | Moderate | 1 | [
[
[
1253,
24,
374
]
],
[
[
1253,
24,
869
],
[
869,
63,
374
]
],
[
[
1253,
24,
770
],
[
770,
64,
374
]
],
[
[
1253,
24,
869
],
[
869,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bevacizumab"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bevacizumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalid... |
DB00816 | DB01267 | 1,674 | 519 | [
"DDInter1346",
"DDInter1381"
] | Orciprenaline | Paliperidone | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
1674,
24,
519
]
],
[
[
1674,
63,
1664
],
[
1664,
1,
519
]
],
[
[
1674,
25,
924
],
[
924,
1,
519
]
],
[
[
1674,
21,
28658
],
[
28658,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Orciprenaline may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
O... |
DB08901 | DB13007 | 1,468 | 1,060 | [
"DDInter1492",
"DDInter642"
] | Ponatinib | Enfortumab vedotin | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1468,
24,
1060
]
],
[
[
1468,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
1468,
63,
129
],
[
129,
23,
1060
]
],
[
[
1468,
63,
1593
],
[
1593... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and ... |
DB06016 | DB12332 | 1,508 | 1,619 | [
"DDInter300",
"DDInter1626"
] | Cariprazine | Rucaparib | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1508,
24,
1619
]
],
[
[
1508,
63,
222
],
[
222,
23,
1619
]
],
[
[
1508,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1508,
63,
1419
],
[
1419... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid an... |
DB08895 | DB13007 | 976 | 1,060 | [
"DDInter1825",
"DDInter642"
] | Tofacitinib | Enfortumab vedotin | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Major | 2 | [
[
[
976,
25,
1060
]
],
[
[
976,
25,
1604
],
[
1604,
23,
1060
]
],
[
[
976,
63,
1593
],
[
1593,
24,
1060
]
],
[
[
976,
25,
270
],
[
270,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
... | Tofacitinib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib ma... |
DB00277 | DB00759 | 1,031 | 1,620 | [
"DDInter1791",
"DDInter1783"
] | Theophylline | Tetracycline | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Moderate | 1 | [
[
[
1031,
24,
1620
]
],
[
[
1031,
24,
1572
],
[
1572,
40,
1620
]
],
[
[
1031,
63,
964
],
[
964,
40,
1620
]
],
[
[
1031,
6,
8374
],
[
8374,... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
]... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Tetrac... |
DB00539 | DB15982 | 11 | 1,339 | [
"DDInter1837",
"DDInter193"
] | Toremifene | Berotralstat | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
11,
24,
1339
]
],
[
[
11,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
11,
24,
283
],
[
283,
23,
1339
]
],
[
[
11,
25,
1213
],
[
1213,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedrat... |
DB00465 | DB09135 | 886 | 1,211 | [
"DDInter1010",
"DDInter967"
] | Ketorolac | Ioxilan | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
886,
25,
1211
]
],
[
[
886,
24,
712
],
[
712,
25,
1211
]
],
[
[
886,
25,
1512
],
[
1512,
25,
1211
]
],
[
[
886,
63,
1645
],
[
1645,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Ioxilan
Ketorolac may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threa... |
DB00794 | DB01268 | 759 | 1,151 | [
"DDInter1521",
"DDInter1731"
] | Primidone | Sunitinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Major | 2 | [
[
[
759,
25,
1151
]
],
[
[
759,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
759,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
759,
21,
29209
],
[
29209,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopr... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Primidone (Compound) causes Anorexia (Side Effect) and Anorexi... |
DB01220 | DB09039 | 1,088 | 1,670 | [
"DDInter1593",
"DDInter629"
] | Rifaximin | Eliglustat | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduc... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1088,
24,
1670
]
],
[
[
1088,
24,
943
],
[
943,
63,
1670
]
],
[
[
1088,
24,
478
],
[
478,
24,
1670
]
],
[
[
1088,
40,
690
],
[
690,
... | [
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
... | Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotin... |
DB01285 | DB09104 | 708 | 286 | [
"DDInter445",
"DDInter1118"
] | Corticotropin | Magnesium hydroxide | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
708,
24,
286
]
],
[
[
708,
63,
88
],
[
88,
23,
286
]
],
[
[
708,
24,
729
],
[
729,
23,
286
]
],
[
[
708,
63,
1326
],
[
1326,
24,... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Penbutol... |
DB00749 | DB08816 | 59 | 578 | [
"DDInter699",
"DDInter1802"
] | Etodolac | Ticagrelor | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
59,
24,
578
]
],
[
[
59,
21,
28762
],
[
28762,
60,
578
]
],
[
[
59,
63,
1578
],
[
1578,
24,
578
]
],
[
[
59,
64,
1172
],
[
1172,
... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Etodolac",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by ... | Etodolac (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Etod... |
DB01072 | DB01083 | 915 | 1,142 | [
"DDInter129",
"DDInter1348"
] | Atazanavir | Orlistat | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
915,
24,
1142
]
],
[
[
915,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
915,
21,
30409
],
[
30409,
60,
1142
]
],
[
[
915,
24,
5
],
[
5,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Atazanavir (Compound) causes Otitis (Side Effect) and Otitis (Side Effect) is caused by Orlistat (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide m... |
DB00019 | DB00072 | 1,257 | 550 | [
"DDInter1405",
"DDInter1846"
] | Pegfilgrastim | Trastuzumab | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Moderate | 1 | [
[
[
1257,
24,
550
]
],
[
[
1257,
24,
869
],
[
869,
63,
550
]
],
[
[
1257,
24,
322
],
[
322,
64,
550
]
],
[
[
1257,
25,
1064
],
[
1064,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and E... |
DB11003 | DB11921 | 748 | 1,019 | [
"DDInter100",
"DDInter492"
] | Anthrax vaccine | Deflazacort | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
748,
24,
1019
]
],
[
[
748,
24,
270
],
[
270,
63,
1019
]
],
[
[
748,
63,
629
],
[
629,
24,
1019
]
],
[
[
748,
24,
1316
],
[
1316,
... | [
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
... | Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimu... |
DB00366 | DB00476 | 1,594 | 109 | [
"DDInter600",
"DDInter608"
] | Doxylamine | Duloxetine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
1594,
24,
109
]
],
[
[
1594,
40,
847
],
[
847,
1,
109
]
],
[
[
1594,
24,
758
],
[
758,
1,
109
]
],
[
[
1594,
63,
1302
],
[
1302,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resemb... | Doxylamine (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Duloxetine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Doxylamine may cause a moderate interaction th... |
DB00092 | DB00688 | 58 | 955 | [
"DDInter40",
"DDInter1251"
] | Alefacept | Mycophenolate mofetil | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Moderate | 1 | [
[
[
58,
24,
955
]
],
[
[
58,
24,
1096
],
[
1096,
40,
955
]
],
[
[
58,
23,
1114
],
[
1114,
62,
955
]
],
[
[
58,
24,
1031
],
[
1031,
2... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor ... |
DB00570 | DB08868 | 147 | 1,011 | [
"DDInter1936",
"DDInter737"
] | Vinblastine | Fingolimod | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
147,
25,
1011
]
],
[
[
147,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
147,
7,
9199
],
[
9199,
45,
1011
]
],
[
[
147,
21,
28714
],
[
28714... | [
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Vinblastine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingo... | Vinblastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Vinblastine (Compound) upregulates SPHK1 (Gene) and SPHK1 (Gene) is bound by Fingolimod (Compound)
Vinblastine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fingolimod (Compound)
Vinblastine... |
DB08889 | DB12834 | 350 | 148 | [
"DDInter299",
"DDInter1649"
] | Carfilzomib | Secnidazole | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
350,
24,
148
]
],
[
[
350,
63,
1593
],
[
1593,
24,
148
]
],
[
[
350,
24,
1480
],
[
1480,
24,
148
]
],
[
[
350,
64,
1510
],
[
1510,
... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazo... |
DB00705 | DB00927 | 441 | 1,559 | [
"DDInter496",
"DDInter712"
] | Delavirdine | Famotidine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
441,
24,
1559
]
],
[
[
441,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
441,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
441,
24,
1384
],
[
138... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compoun... | Delavirdine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Delavirdine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and M... |
DB00687 | DB11601 | 870 | 1,270 | [
"DDInter747",
"DDInter1889"
] | Fludrocortisone | Tuberculin purified protein derivative | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
870,
24,
1270
]
],
[
[
870,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
870,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
870,
1,
1486
],
[
1486,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Fludrocortisone may lead to a major life threatening interaction when taken w... |
DB00342 | DB11791 | 1,181 | 785 | [
"DDInter1770",
"DDInter287"
] | Terfenadine | Capmatinib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1181,
24,
785
]
],
[
[
1181,
25,
868
],
[
868,
24,
785
]
],
[
[
1181,
24,
322
],
[
322,
24,
785
]
],
[
[
1181,
64,
600
],
[
600,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemuraf... | Terfenadine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may ca... |
DB00443 | DB01124 | 251 | 1,411 | [
"DDInter195",
"DDInter1828"
] | Betamethasone | Tolbutamide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
251,
24,
1411
]
],
[
[
251,
24,
959
],
[
959,
40,
1411
]
],
[
[
251,
63,
245
],
[
245,
40,
1411
]
],
[
[
251,
7,
2789
],
[
2789,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Co... |
DB01122 | DB12267 | 158 | 1,476 | [
"DDInter61",
"DDInter233"
] | Ambenonium | Brigatinib | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
158,
24,
1476
]
],
[
[
158,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
158,
63,
1528
],
[
1528,
24,
1476
]
],
[
[
158,
24,
1011
],
[
1011,
... | [
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ambenonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
... | Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ambenonium may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physo... |
DB00476 | DB06694 | 109 | 31 | [
"DDInter608",
"DDInter1952"
] | Duloxetine | Xylometazoline (nasal) | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Xylometazoline is an alkylbenzene. | Moderate | 1 | [
[
[
109,
24,
31
]
],
[
[
109,
24,
144
],
[
144,
63,
31
]
],
[
[
109,
24,
1148
],
[
1148,
24,
31
]
],
[
[
109,
40,
1302
],
[
1302,
24... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Du... |
DB00279 | DB01359 | 1,152 | 729 | [
"DDInter1074",
"DDInter1417"
] | Liothyronine | Penbutolol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Minor | 0 | [
[
[
1152,
23,
729
]
],
[
[
1152,
23,
461
],
[
461,
1,
729
]
],
[
[
1152,
23,
699
],
[
699,
40,
729
]
],
[
[
1152,
21,
28882
],
[
28882,
... | [
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Penbutolol"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
[
... | Liothyronine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Liothyronine... |
DB11601 | DB11793 | 1,270 | 738 | [
"DDInter1889",
"DDInter1297"
] | Tuberculin purified protein derivative | Niraparib | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1270,
24,
738
]
],
[
[
1270,
63,
1213
],
[
1213,
24,
738
]
],
[
[
1270,
24,
1619
],
[
1619,
63,
738
]
],
[
[
1270,
24,
351
],
[
351,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases w... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tuberculin purified protein derivative may cause a moderate interaction that could exac... |
DB01159 | DB13074 | 419 | 877 | [
"DDInter854",
"DDInter1110"
] | Halothane | Macimorelin | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
419,
25,
877
]
],
[
[
419,
62,
112
],
[
112,
23,
877
]
],
[
[
419,
24,
913
],
[
913,
24,
877
]
],
[
[
419,
63,
770
],
[
770,
24,... | [
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apal... |
DB00701 | DB01190 | 1,091 | 568 | [
"DDInter90",
"DDInter398"
] | Amprenavir | Clindamycin | Amprenavir is a protease inhibitor used to treat HIV infection. | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
1091,
24,
568
]
],
[
[
1091,
6,
8374
],
[
8374,
45,
568
]
],
[
[
1091,
21,
29278
],
[
29278,
60,
568
]
],
[
[
1091,
23,
609
],
[
609,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Amprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Amprenavir (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Clindamycin (Compound)
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromyci... |
DB00316 | DB00682 | 474 | 126 | [
"DDInter14",
"DDInter1951"
] | Acetaminophen | Warfarin | Acetaminophen (paracetamol), also commonly known as _Tylenol_, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the ... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
474,
24,
126
]
],
[
[
474,
6,
3486
],
[
3486,
45,
126
]
],
[
[
474,
24,
663
],
[
663,
23,
126
]
],
[
[
474,
24,
1017
],
[
1017,
... | [
[
[
"Acetaminophen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Acetaminophen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compoun... | Acetaminophen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound)
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Acetaminophen ... |
DB00677 | DB12267 | 775 | 1,476 | [
"DDInter984",
"DDInter233"
] | Isoflurophate (ophthalmic) | Brigatinib | Diisopropyl fluorophosphate is a dialkyl phosphate. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
775,
24,
1476
]
],
[
[
775,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
775,
24,
1011
],
[
1011,
25,
1476
]
],
[
[
775,
24,
1276
],
[
1276,
... | [
[
[
"Isoflurophate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Isoflurophate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
... | Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Isoflurophate may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Isoflu... |
DB00794 | DB08901 | 759 | 1,468 | [
"DDInter1521",
"DDInter1492"
] | Primidone | Ponatinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
759,
24,
1468
]
],
[
[
759,
25,
478
],
[
478,
24,
1468
]
],
[
[
759,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
759,
18,
3741
],
[
3741,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Primidone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Primidone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Primidone (Compound) downregulates OXA1... |
DB01116 | DB08907 | 601 | 1,344 | [
"DDInter1872",
"DDInter280"
] | Trimethaphan | Canagliflozin | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
601,
24,
1344
]
],
[
[
601,
24,
549
],
[
549,
1,
1344
]
],
[
[
601,
63,
1486
],
[
1486,
24,
1344
]
],
[
[
601,
24,
1019
],
[
1019,
... | [
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a mo... |
DB00468 | DB00582 | 1,424 | 1,622 | [
"DDInter1557",
"DDInter1946"
] | Quinine | Voriconazole | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
1424,
24,
1622
]
],
[
[
1424,
6,
21998
],
[
21998,
45,
1622
]
],
[
[
1424,
21,
29076
],
[
29076,
60,
1622
]
],
[
[
1424,
23,
752
],
[
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v... | Quinine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Voriconazole (Compound)
Quinine (Compound) causes Liver function test abnormal (Side Effect) and Liver function test abnormal (Side Effect) is caused by Voriconazole (Compound)
Quinine may cause a minor interaction that can limit cli... |
DB04948 | DB12141 | 1,084 | 971 | [
"DDInter1083",
"DDInter817"
] | Lofexidine | Gilteritinib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1084,
24,
971
]
],
[
[
1084,
62,
112
],
[
112,
23,
971
]
],
[
[
1084,
63,
485
],
[
485,
24,
971
]
],
[
[
1084,
24,
823
],
[
823,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and P... |
DB00731 | DB01032 | 1,144 | 824 | [
"DDInter1269",
"DDInter1522"
] | Nateglinide | Probenecid | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Moderate | 1 | [
[
[
1144,
24,
824
]
],
[
[
1144,
24,
1411
],
[
1411,
63,
824
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
824
]
],
[
[
1144,
21,
28722
],
[
28722... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probenecid"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Probenecid (Compound)
Nateglinide (C... |
DB08889 | DB11995 | 350 | 1,634 | [
"DDInter299",
"DDInter143"
] | Carfilzomib | Avatrombopag | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Major | 2 | [
[
[
350,
25,
1634
]
],
[
[
350,
24,
1613
],
[
1613,
24,
1634
]
],
[
[
350,
63,
912
],
[
912,
24,
1634
]
],
[
[
350,
24,
1613
],
[
1613,
... | [
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avatrombopag"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00213 | DB05294 | 837 | 1,069 | [
"DDInter1388",
"DDInter1917"
] | Pantoprazole | Vandetanib | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Minor | 0 | [
[
[
837,
23,
1069
]
],
[
[
837,
25,
1195
],
[
1195,
40,
1069
]
],
[
[
837,
24,
883
],
[
883,
40,
1069
]
],
[
[
837,
6,
17404
],
[
17404,
... | [
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erlotinib"
],
[
"Erlotinib... | Pantoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Vandetanib (Compound)
Pantoprazole (C... |
DB00790 | DB06723 | 664 | 115 | [
"DDInter1431",
"DDInter58"
] | Perindopril | Aluminum hydroxide | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
664,
23,
115
]
],
[
[
664,
21,
28845
],
[
28845,
60,
115
]
],
[
[
664,
40,
1058
],
[
1058,
23,
115
]
],
[
[
664,
63,
870
],
[
870,
... | [
[
[
"Perindopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Perindopril",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is ca... | Perindopril (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Aluminum hydroxide (Compound)
Perindopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Perindopril may cause a moderate int... |
DB09570 | DB15965 | 1,480 | 1,330 | [
"DDInter1002",
"DDInter1270"
] | Ixazomib | Naxitamab | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
1480,
24,
1330
]
],
[
[
1480,
63,
14
],
[
14,
24,
1330
]
],
[
[
1480,
24,
148
],
[
148,
24,
1330
]
],
[
[
1480,
64,
375
],
[
375,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnid... |
DB04865 | DB13928 | 4 | 1,385 | [
"DDInter1335",
"DDInter1660"
] | Omacetaxine mepesuccinate | Semaglutide | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
4,
24,
1385
]
],
[
[
4,
24,
637
],
[
637,
24,
1385
]
],
[
[
4,
63,
891
],
[
891,
24,
1385
]
],
[
[
4,
64,
695
],
[
695,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Omacetaxine mepesuccinate may cause a moderate int... |
DB01319 | DB11703 | 34 | 405 | [
"DDInter777",
"DDInter9"
] | Fosamprenavir | Acalabrutinib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
34,
25,
405
]
],
[
[
34,
63,
1051
],
[
1051,
24,
405
]
],
[
[
34,
25,
951
],
[
951,
24,
405
]
],
[
[
34,
25,
982
],
[
982,
63,
... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Fosamprenavir may lead to a major life threatening interaction when taken with Palbociclib a... |
DB00758 | DB06754 | 1,347 | 707 | [
"DDInter413",
"DDInter471"
] | Clopidogrel | Danaparoid | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1347,
25,
707
]
],
[
[
1347,
23,
944
],
[
944,
62,
707
]
],
[
[
1347,
24,
1496
],
[
1496,
63,
707
]
],
[
[
1347,
24,
901
],
[
901,
... | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib... |
DB06273 | DB14711 | 980 | 779 | [
"DDInter1824",
"DDInter1680"
] | Tocilizumab | Smallpox (Vaccinia) Vaccine, Live | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
980,
25,
779
]
],
[
[
980,
64,
1064
],
[
1064,
25,
779
]
],
[
[
980,
63,
147
],
[
147,
25,
779
]
],
[
[
980,
25,
1259
],
[
1259,
... | [
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Tocilizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastin... |
DB00719 | DB01057 | 1,219 | 1,318 | [
"DDInter149",
"DDInter615"
] | Azatadine | Echothiophate (ophthalmic) | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Ecothiopate is the phosphorothioate obtained by formal condensation of diethyl phosphate with N,N,N-trimethyl-2-sulfanylethanaminium. An irreversible acetylcholinesterase inhibitor, its iodide salt is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inad... | Moderate | 1 | [
[
[
1219,
24,
1318
]
],
[
[
1219,
40,
830
],
[
830,
63,
1318
]
],
[
[
1219,
24,
100
],
[
100,
24,
1318
]
],
[
[
1219,
24,
272
],
[
272,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Echothiophate"
]
],
[
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a mo... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Echothiophate
Azatadine may cause a moderate interaction that co... |
DB00285 | DB09065 | 1,100 | 760 | [
"DDInter1927",
"DDInter424"
] | Venlafaxine | Cobicistat | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1100,
24,
760
]
],
[
[
1100,
24,
1374
],
[
1374,
23,
760
]
],
[
[
1100,
24,
723
],
[
723,
24,
760
]
],
[
[
1100,
40,
534
],
[
534,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apre... |
DB00288 | DB01124 | 1,103 | 1,411 | [
"DDInter63",
"DDInter1828"
] | Amcinonide | Tolbutamide | Amcinonide is a corticosteroid. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Minor | 0 | [
[
[
1103,
23,
1411
]
],
[
[
1103,
23,
959
],
[
959,
40,
1411
]
],
[
[
1103,
62,
245
],
[
245,
40,
1411
]
],
[
[
1103,
21,
28703
],
[
28703... | [
[
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
],
[
... | Amcinonide may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Amcinonide may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Am... |
DB00213 | DB01416 | 837 | 1,024 | [
"DDInter1388",
"DDInter326"
] | Pantoprazole | Cefpodoxime | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
837,
24,
1024
]
],
[
[
837,
24,
665
],
[
665,
40,
1024
]
],
[
[
837,
24,
1462
],
[
1462,
1,
1024
]
],
[
[
837,
21,
29044
],
[
29044,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefpodoxime (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefpodoxime (Comp... |
DB00590 | DB01246 | 1,433 | 820 | [
"DDInter592",
"DDInter45"
] | Doxazosin | Alimemazine | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1433,
24,
820
]
],
[
[
1433,
24,
104
],
[
104,
40,
820
]
],
[
[
1433,
24,
401
],
[
401,
24,
820
]
],
[
[
1433,
21,
28662
],
[
28662,
... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB00685 | DB01101 | 1,299 | 60 | [
"DDInter1887",
"DDInter285"
] | Trovafloxacin | Capecitabine | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Minor | 0 | [
[
[
1299,
23,
60
]
],
[
[
1299,
21,
28906
],
[
28906,
60,
60
]
],
[
[
1299,
1,
872
],
[
872,
62,
60
]
],
[
[
1299,
24,
460
],
[
460,
... | [
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastroenteritis"
],
[
"Gastroenteritis",
"{u} (Si... | Trovafloxacin (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Capecitabine (Compound)
Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Trovafloxacin may ca... |
DB00687 | DB01208 | 870 | 945 | [
"DDInter747",
"DDInter1705"
] | Fludrocortisone | Sparfloxacin | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
870,
25,
945
]
],
[
[
870,
25,
739
],
[
739,
1,
945
]
],
[
[
870,
64,
1176
],
[
1176,
1,
945
]
],
[
[
870,
21,
28814
],
[
28814,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxaci... | Fludrocortisone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Fludrocortisone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Fludroco... |
DB01263 | DB06176 | 859 | 1,342 | [
"DDInter1494",
"DDInter1616"
] | Posaconazole | Romidepsin | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
859,
24,
1342
]
],
[
[
859,
62,
112
],
[
112,
23,
1342
]
],
[
[
859,
63,
485
],
[
485,
24,
1342
]
],
[
[
859,
24,
1616
],
[
1616,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Posaconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and... |
DB00543 | DB00619 | 87 | 1,419 | [
"DDInter82",
"DDInter909"
] | Amoxapine | Imatinib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
87,
24,
1419
]
],
[
[
87,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
87,
21,
28762
],
[
28762,
60,
1419
]
],
[
[
87,
25,
222
],
[
222,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Amoxapine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Imatinib (Compound)
Amoxapine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a min... |
DB00404 | DB06282 | 523 | 516 | [
"DDInter54",
"DDInter1053"
] | Alprazolam | Levocetirizine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
523,
24,
516
]
],
[
[
523,
62,
1031
],
[
1031,
23,
516
]
],
[
[
523,
24,
1074
],
[
1074,
63,
516
]
],
[
[
523,
63,
701
],
[
701,
... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
... | Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and ... |
DB01064 | DB01168 | 1,148 | 1,053 | [
"DDInter987",
"DDInter1526"
] | Isoprenaline | Procarbazine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1148,
24,
1053
]
],
[
[
1148,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1148,
64,
246
],
[
246,
23,
1053
]
],
[
[
1148,
63,
739
],
[
739... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is ... | Isoprenaline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Isoprenaline may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Iso... |
DB00721 | DB00795 | 1,207 | 50 | [
"DDInter1525",
"DDInter1725"
] | Procaine | Sulfasalazine | A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-expe... | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
1207,
24,
50
]
],
[
[
1207,
18,
18226
],
[
18226,
57,
50
]
],
[
[
1207,
25,
1455
],
[
1455,
64,
50
]
],
[
[
1207,
18,
18226
],
[
18226... | [
[
[
"Procaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Procaine",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v}... | Procaine (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Sulfasalazine (Compound)
Procaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Sulfasalazine
Procaine (Compound) downregu... |
DB00366 | DB11823 | 1,594 | 858 | [
"DDInter600",
"DDInter673"
] | Doxylamine | Esketamine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Eske... | Moderate | 1 | [
[
[
1594,
24,
858
]
],
[
[
1594,
35,
272
],
[
272,
24,
858
]
],
[
[
1594,
24,
506
],
[
506,
24,
858
]
],
[
[
1594,
63,
1242
],
[
1242,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken w... | Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Doxylamine may cause a moderate inte... |
DB00771 | DB01224 | 262 | 623 | [
"DDInter397",
"DDInter1553"
] | Clidinium | Quetiapine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
262,
24,
623
]
],
[
[
262,
63,
695
],
[
695,
1,
623
]
],
[
[
262,
24,
1178
],
[
1178,
1,
623
]
],
[
[
262,
6,
7992
],
[
7992,
45... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Quetiapine (Comp... |
DB00963 | DB01124 | 1,263 | 1,411 | [
"DDInter241",
"DDInter1828"
] | Bromfenac | Tolbutamide | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1263,
24,
1411
]
],
[
[
1263,
24,
959
],
[
959,
40,
1411
]
],
[
[
1263,
63,
245
],
[
245,
40,
1411
]
],
[
[
1263,
18,
9205
],
[
9205,
... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
... |
DB00023 | DB00065 | 305 | 581 | [
"DDInter127",
"DDInter923"
] | Asparaginase Escherichia coli | Infliximab | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory... | Major | 2 | [
[
[
305,
25,
581
]
],
[
[
305,
24,
221
],
[
221,
63,
581
]
],
[
[
305,
24,
912
],
[
912,
24,
581
]
],
[
[
305,
63,
1451
],
[
1451,
2... | [
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poli... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Asparagin... |
DB01236 | DB11978 | 679 | 124 | [
"DDInter1664",
"DDInter822"
] | Sevoflurane | Glasdegib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
679,
24,
124
]
],
[
[
679,
62,
112
],
[
112,
23,
124
]
],
[
[
679,
63,
475
],
[
475,
24,
124
]
],
[
[
679,
24,
1342
],
[
1342,
2... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Sevoflurane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morph... |
DB00341 | DB00832 | 1,242 | 499 | [
"DDInter343",
"DDInter1446"
] | Cetirizine | Phensuximide | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. | Moderate | 1 | [
[
[
1242,
24,
499
]
],
[
[
1242,
24,
902
],
[
902,
40,
499
]
],
[
[
1242,
24,
849
],
[
849,
63,
499
]
],
[
[
1242,
24,
1594
],
[
1594,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Phensuximide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could e... |
DB00106 | DB01044 | 618 | 246 | [
"DDInter4",
"DDInter809"
] | Abarelix | Gatifloxacin | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
618,
25,
246
]
],
[
[
618,
25,
1176
],
[
1176,
1,
246
]
],
[
[
618,
24,
872
],
[
872,
40,
246
]
],
[
[
618,
23,
112
],
[
112,
23... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u}... | Abarelix may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Gatifloxacin (Compound)
Abareli... |
DB00682 | DB09117 | 126 | 957 | [
"DDInter1951",
"DDInter1391"
] | Warfarin | Paraldehyde | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Minor | 0 | [
[
[
126,
23,
957
]
],
[
[
126,
24,
1264
],
[
1264,
24,
957
]
],
[
[
126,
1,
1376
],
[
1376,
24,
957
]
],
[
[
126,
24,
1264
],
[
1264,
... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paraldehyde"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Dox... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Warfarin (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that coul... |
DB01210 | DB09333 | 668 | 278 | [
"DDInter1050",
"DDInter963"
] | Levobunolol (ophthalmic) | Iopodic acid | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
668,
24,
278
]
],
[
[
668,
40,
461
],
[
461,
24,
278
]
],
[
[
668,
24,
1527
],
[
1527,
24,
278
]
],
[
[
668,
63,
808
],
[
808,
2... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate ... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levobunolol may cause a moderate interaction that could ex... |
DB08889 | DB09121 | 350 | 1,328 | [
"DDInter299",
"DDInter140"
] | Carfilzomib | Aurothioglucose | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
350,
24,
1328
]
],
[
[
350,
63,
367
],
[
367,
24,
1328
]
],
[
[
350,
64,
581
],
[
581,
24,
1328
]
],
[
[
350,
25,
375
],
[
375,
... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carfilzomib may lead to a major life threatening interaction when taken with Inflixima... |
DB00795 | DB13874 | 50 | 1,501 | [
"DDInter1725",
"DDInter639"
] | Sulfasalazine | Enasidenib | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
50,
24,
1501
]
],
[
[
50,
63,
663
],
[
663,
24,
1501
]
],
[
[
50,
24,
1619
],
[
1619,
24,
1501
]
],
[
[
50,
25,
1510
],
[
1510,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib a... |
DB00804 | DB14881 | 1,507 | 180 | [
"DDInter543",
"DDInter1329"
] | Dicyclomine | Oliceridine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1507,
24,
180
]
],
[
[
1507,
24,
401
],
[
401,
24,
180
]
],
[
[
1507,
63,
85
],
[
85,
24,
180
]
],
[
[
1507,
63,
1425
],
[
1425,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and A... |
DB01234 | DB13179 | 1,220 | 68 | [
"DDInter513",
"DDInter1882"
] | Dexamethasone | Troleandomycin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
1220,
24,
68
]
],
[
[
1220,
63,
1101
],
[
1101,
23,
68
]
],
[
[
1220,
25,
466
],
[
466,
23,
68
]
],
[
[
1220,
24,
309
],
[
309,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamid... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.